(2019 US endorses tobacco pouches as less risky than cigarettes) |
|||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 8: | Line 8: | ||
=Tobacco Pouches - Studies, Surveys, Papers= | =Tobacco Pouches - Studies, Surveys, Papers= | ||
Please see [[SLT]] page for more details | |||
=Tobacco Free Nicotine Pouches - Studies, Surveys, Papers= | |||
===2023: [https://www.nature.com/articles/s41415-023-6383-7 Nicotine pouches: a review for the dental team]=== | |||
*Nicotine pouches are a new product that the dental professional should be aware of, particularly in smokers and ex-smokers. They are likely to have a relatively low-risk profile, similar to other forms of orally administered nicotine; however, the prolonged and regular use may give increased risk of local oral problems. Further research is required. | |||
= | ===2021: [https://link.springer.com/article/10.1007%2 | ||
Fs13318-021-00742-9 A Randomised Study to Investigate the Nicotine Pharmacokinetics of Oral Nicotine Pouches and a Combustible Cigarette]=== | |||
*NPs (Nicotine Pouches) can provide nicotine in amounts sufficient to replicate cigarette smokers' nicotine uptake following a switch from conventional cigarettes to these potentially less harmful NP products. | |||
*Citation: McEwan, M., Azzopardi, D., Gale, N. et al. A Randomised Study to Investigate the Nicotine Pharmacokinetics of Oral Nicotine Pouches and a Combustible Cigarette. Eur J Drug Metab Pharmacokinet (2021). doi.org/10.1007/s13318-021-00742-9 | |||
*Acknowledgement: All authors are current employees of British American Tobacco (Investments) Limited except JM who is an employee of RAI Services Company and IMF who is a consultant contracted by British American Tobacco (Investments) Limited. | |||
===2020: [https://onlinelibrary.wiley.com/doi/10.1111/ajad.13020 Initial Information on a Novel Nicotine Product]=== | |||
*Nonusers of tobacco had very little interest in ZYN. Smokeless tobacco users are not only more interested and likely to buy ZYN than other tobacco users, they were the largest group of regular users. | |||
*The first assessment of a new nicotine product, ZYN, suggests that current and former tobacco users may perceive ZYN as a reduced‐risk product. ZYN potentially could be used as a smoking/tobacco‐cessation aid based on reasons of current users. | |||
*[https://sci-hub.do/10.1111/ajad.13020 PDF Version] | |||
*Citation: Plurphanswat, N., Hughes, J. R., Fagerström, K., & Rodu, B. (2020). Initial Information on a Novel Nicotine Product. The American Journal on Addictions. doi:10.1111/ajad.13020 | |||
*Brad Rodu’s Blog: [https://rodutobaccotruth.blogspot.com/2020/05/first-study-of-zyn-novel-consumer.html First Study of ZYN, A Novel Consumer Nicotine Product] | |||
===2020: [https://pubmed.ncbi.nlm.nih.gov/32319528/ Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff]=== | ===2020: [https://pubmed.ncbi.nlm.nih.gov/32319528/ Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff]=== | ||
*The two higher doses of ZYN (6 and 8 mg) deliver nicotine as quickly and to a similar extent as existing smokeless products, with no significant adverse effects. | *The two higher doses of ZYN (6 and 8 mg) deliver nicotine as quickly and to a similar extent as existing smokeless products, with no significant adverse effects. | ||
*Citation: Lunell E, Fagerström K, Hughes J, Pendrill R. Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff. Nicotine Tob Res. 2020 Oct 8;22(10):1757-1763. doi: 10.1093/ntr/ntaa068. PMID: 32319528. | *Citation: Lunell E, Fagerström K, Hughes J, Pendrill R. Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff. Nicotine Tob Res. 2020 Oct 8;22(10):1757-1763. doi: 10.1093/ntr/ntaa068. PMID: 32319528. | ||
===2020: [https://www.sciencedirect.com/science/article/pii/S0278691520306037 An approach for the extract generation and toxicological assessment of tobacco-free ‘modern’ oral nicotine pouches]=== | ===2020: [https://www.sciencedirect.com/science/article/pii/S0278691520306037 An approach for the extract generation and toxicological assessment of tobacco-free ‘modern’ oral nicotine pouches]=== | ||
| Line 22: | Line 36: | ||
*Acknowledgement: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: BAT funded the project and all authors were employees of BAT at the time of the study conduct. LYFT tobacco-free modern oral nicotine pouches are manufactured and supplied by BAT. | *Acknowledgement: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: BAT funded the project and all authors were employees of BAT at the time of the study conduct. LYFT tobacco-free modern oral nicotine pouches are manufactured and supplied by BAT. | ||
=Articles, Blogs, Videos (Tobacco and Tobacco Free Pouches)= | |||
= | |||
===2021 Blog: [https://www.idwala.co.uk/blog/can-nicotine-pouches-alleviate-harm-reduction-hurdles-in-emerging-markets Can Nicotine Pouches Alleviate Harm Reduction Hurdles in Emerging Markets?]=== | |||
*Compares cost in various countries to other forms of tobacco Harm Reduction Products. | |||
*There is a significant role for nicotine pouches in tobacco harm reduction in Emerging Markets, particularly in countries where oral tobacco use is prevalent. | |||
*In theory, regulators should look more favourably on the category, but this has not proven to be the case. In part, the industry needs to take a more proactive approach and engage with regulators and local stakeholders, where appropriate, before launching new products. | |||
*Nicotine pouches don't require consumers to buy often prohibitively expensive devices. Still, relatively high current production costs make it challenging to earn the returns needed to facilitate meaningful investment in many developing countries. Over time, this could be addressed by a combination of appropriate excise-tax regimes and reduced input costs. | |||
edits